
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs Inc. is positioned favorably within the biotechnology sector, particularly as patient adoption of biologics for inflammatory bowel disease (IBD) has increased significantly—rising from 5% to 16% for ulcerative colitis (UC) and from 22% to 44% for Crohn's disease (CD) between 2007 and 2015. The company's lead program, SL-325, a potentially first-in-class DR3 antagonist antibody, is anticipated to capture a robust market share, bolstered by a highlighting of conservative launch estimates that suggest continued growth in sales. Furthermore, the focus on developing SL-425 and other preclinical DR3-based bispecific antibodies indicates a strong pipeline that could enhance Shattuck Labs's market position within IBD treatment options.
Bears say
Shattuck Labs Inc faces a negative outlook due to substantial uncertainties surrounding the efficacy and safety of its lead programs, which may not meet necessary immunogenicity standards, potentially hindering development and market acceptance. Additionally, the persistent underestimation of market growth and advanced therapy utilization in inflammatory bowel disease (IBD) could impact the company’s commercial projections and overall financial performance. Furthermore, the company's leading programs, SL-325 and SL-425, operate in a complex competitive landscape marked by increasing use of biologics that may result in declining surgery rates, thereby affecting market dynamics and revenue potential.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares